Samantha DiGrande

Availability of TNF-alpha inhibitor biosimilars in Southern European markets led to lowered costs within the drug class, even after an increased consumption volume for these therapies.

Study shows a statistically significant improvement in inflammatory syndrome after a fecal microbiota transplant in patients coinfected with COVID-19 and clostridioides difficile.

Most individuals who used cannabis to manage their chronic pain reported using it in place of other pain medications, including opioids.

Multisystem inflammatory syndrome typically presents approximately 1 month after a COVID infection, occasionally resulting in cardiac complications in previously healthy children.

Enhanced care involves a pharmacy technician serving as a patient navigator who screens for health-related social needs quarterly and helps to connect patients with community resources.

During the COVID-19 pandemic, patients were able to utilize telehealth services to receive care more conveniently, which may reduce the cost of care.

Study notes that evaluating changes in the proportion of hospitalizations for mental health conditions among adolescents is vital to ensure the prioritization of public health programs that address psychiatric health care needs that emerged during the COVID-19 pandemic.

Patients with depression were significantly less likely to have adequate 12-month adherence to antiplatelets, β-blockers, and statins than those without depression.

Investing in outpatient behavioral health treatment pathways found to be a cost-effective measure to better manage both medical and behavioral conditions.

Respiratory syncytial virus- and rhinovirus-induced wheezing illnesses differ from each other at multiple levels.

Commonly published metformin study designs in patients with type 2 diabetes may not be sufficiently addressing residual confounding.

Due to the correlation between virologic suppression and antiretroviral therapy adherence, understanding the impediments of adherence is of the utmost importance.

A recent study showed that flavonoid-rich cocoa improved fatigue by 45% in patients with relapsing and remitting multiple sclerosis.

In a real-world setting, long-term outcomes were more favorable following early intensive therapy when compared with first-line moderate-efficacy diseased modifying therapy.

A federal appropriations bill will not include bipartisan provision that would have required drug manufacturers to be more transparent with costs to consumers after it was blocked by House Republicans.

A recent study discovered a new way to use bioinformatics to determine how a patient’s immune system responds to immunotherapy.

A blood-based test to assess tumor mutational burden was recently discovered as being able to accurately identify patients with non–small cell lung cancer (NSCLC) who could benefit from checkpoint inhibitor treatment.

KEYNOTE-048 has met a primary end point of overall survival.

A recent systematic review and meta-analysis found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.

Genentech announced that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer.

Hepatocellular carcinoma is the most common type of liver cancer in adults.

A retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS)

According to the case study, an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.